{"id":4141,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/levetiracetam-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"levetiracetam-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/levetiracetam-txt\/","title":{"rendered":"Levetiracetam.txt"},"content":{"rendered":"

Levetiracetam <\/h1>\n

CLINICAL USE <\/H3>
\nAnti-epileptic agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>250 mg \u2013 1.5 g twice daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :170.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 66 (95% drug + metabolite)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.5\u20130.7<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :6\u20138\/25

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>50\u201379 500\u20131000 mg twice daily130\u201349 250\u2013750 mg twice daily1<30 250\u2013500 mg twice daily1

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. 750 mg loading dose then 500\u20131000 mg daily<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. 750 mg loading dose then 500\u20131000 mg once daily
  • HDF\/high flux &nbsp :Dialysed. 750 mg loading dose then 500\u20131000 mg once daily
  • CAV\/VVHD &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR=30\u201349 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered)\n
  • Antimalarials: mefloquine antagonises anticonvulsant effect; chloroquine and hydroxychloroquine occasionally reduce seizure threshold

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV

    Rate of Administration <\/H4>15 minutes

    Comments<\/H4>Dilute in 100 mL sodium chloride or glucose 5%

    OTHER INFORMATION <\/H4>51% of the dose is removed with 4 hours of haemodialysisThe inactive metabolite (ucb L057) accumulates in renal failure
    \n","protected":false},"excerpt":{"rendered":"

    Levetiracetam CLINICAL USE Anti-epileptic agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4141","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4141"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4141\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}